These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3955 related articles for article (PubMed ID: 25920090)

  • 1. NAFLD: a multisystem disease.
    Byrne CD; Targher G
    J Hepatol; 2015 Apr; 62(1 Suppl):S47-64. PubMed ID: 25920090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the association between developing a fatty liver and subsequent cardio-metabolic complications.
    Miele L; Targher G
    Expert Rev Gastroenterol Hepatol; 2015; 9(10):1243-5. PubMed ID: 26224399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extrahepatic Diseases and NAFLD: The Triangular Relationship between NAFLD, Type 2-Diabetes and Dysbiosis.
    Scorletti E; Byrne CD
    Dig Dis; 2016; 34 Suppl 1():11-8. PubMed ID: 27548822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease.
    Targher G; Byrne CD
    Nat Rev Nephrol; 2017 May; 13(5):297-310. PubMed ID: 28218263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease.
    Byrne CD; Targher G
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1155-61. PubMed ID: 24743428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-alcoholic fatty liver disease and risk of cardiovascular disease.
    Lonardo A; Sookoian S; Pirola CJ; Targher G
    Metabolism; 2016 Aug; 65(8):1136-50. PubMed ID: 26477269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease - A multisystem disease?
    Mikolasevic I; Milic S; Turk Wensveen T; Grgic I; Jakopcic I; Stimac D; Wensveen F; Orlic L
    World J Gastroenterol; 2016 Nov; 22(43):9488-9505. PubMed ID: 27920470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complications, morbidity and mortality of nonalcoholic fatty liver disease.
    Mantovani A; Scorletti E; Mosca A; Alisi A; Byrne CD; Targher G
    Metabolism; 2020 Oct; 111S():154170. PubMed ID: 32006558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease.
    Luo J; Xu L; Li J; Zhao S
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):193-9. PubMed ID: 25563143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular Disease in Patients with Nonalcoholic Fatty Liver Disease.
    Potze W; Siddiqui MS; Sanyal AJ
    Semin Thromb Hemost; 2015 Jul; 41(5):488-93. PubMed ID: 26049073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD).
    Johnston MP; Patel J; Byrne CD
    Curr Pharm Des; 2020; 26(10):1079-1092. PubMed ID: 32003662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?
    Targher G; Marchesini G; Byrne CD
    Diabetes Metab; 2016 Jun; 42(3):142-56. PubMed ID: 27142870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications.
    Targher G; Byrne CD
    J Clin Endocrinol Metab; 2013 Feb; 98(2):483-95. PubMed ID: 23293330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.
    Adams LA; Anstee QM; Tilg H; Targher G
    Gut; 2017 Jun; 66(6):1138-1153. PubMed ID: 28314735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cardiovascular Risk in Patients with Non-alcoholic Fatty Liver Disease].
    Kim HS; Cho YK
    Korean J Gastroenterol; 2017 Jun; 69(6):333-340. PubMed ID: 28637101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ectopic fat, insulin resistance and non-alcoholic fatty liver disease.
    Byrne CD
    Proc Nutr Soc; 2013 Nov; 72(4):412-9. PubMed ID: 23668723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NAFLD and cardiovascular diseases: a clinical review.
    Kasper P; Martin A; Lang S; Kütting F; Goeser T; Demir M; Steffen HM
    Clin Res Cardiol; 2021 Jul; 110(7):921-937. PubMed ID: 32696080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Banting memorial lecture 2022: 'Type 2 diabetes and nonalcoholic fatty liver disease: Partners in crime'.
    Byrne CD
    Diabet Med; 2022 Oct; 39(10):e14912. PubMed ID: 35790023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A concise review of non-alcoholic fatty liver disease.
    Than NN; Newsome PN
    Atherosclerosis; 2015 Mar; 239(1):192-202. PubMed ID: 25617860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 198.